JW Pharmaceutical (001060.KS) reported a 7.7% increase in revenue last year, driven by growth in its prescription drug business.
The company disclosed preliminary earnings Thursday showing consolidated revenue of 774.8 billion won ($540 million), up 7.7% year-on-year, with operating profit rising 13.5% to 93.6 billion won. Net profit, however, fell 5.15% to 61.7 billion won due to additional corporate tax payments.
"Sales growth was led by our portfolio of original prescription drugs," a JW Pharmaceutical official said.
Prescription drug revenue reached 636.6 billion won, up 9.1% from 583.7 billion won in the previous year. Livaro Zet, an improved combination drug for dyslipidemia based on pitavastatin, posted sales of 101 billion won, a 32.5% increase. The broader Livaro product line—including Livaro, Livaro Zet, and Livaro V—generated combined revenue of 189.3 billion won, up 16.9%.
Hemlibra, a hemophilia treatment, saw sales surge 48.5% to 72.6 billion won, while Ferinject, a high-dose intravenous iron injection, recorded 17.7 billion won in revenue, up 22.5%.
The infusion solutions segment grew 2.4% to 253 billion won from 247 billion won in 2024. Within this category, the Winuf line of premium total parenteral nutrition products achieved sales of 84.1 billion won, a 6.6% increase.
Over-the-counter drug revenue declined 4.5% to 49.3 billion won.